Meridian Medical Technologies, LLC

Meridian Medical Technologies, LLC, doing business as Meridian Medical Technologies Inc., manufactures and supplies autoinjector devices and nerve agent antidote treatments to federal agencies as a prime contractor, operating under full-and-open competitive procurement without set-aside designations. The company is a wholly-owned subsidiary of Pfizer Inc. and is organized as a for-profit limited liability company headquartered in St. Louis, Missouri, with manufacturing and distribution operations also in Columbia, Maryland. Primary work centers on DuoDote autoinjectors (combining atropine and pralidoxime chloride) and associated medical training devices for chemical and biological defense preparedness, strategic national stockpiling, and emergency medical response across defense, civilian health, and law enforcement agencies.

Meridian operates exclusively as a prime contractor—418 awards spanning from 1981 to April 2026, all prime, with no subcontract footprint. Customer concentration is extreme and agency-specific. The Defense Logistics Agency Troop Support Medical dominates the award count (178 awards, $1.01 billion combined potential value), followed by the Defense Logistics Agency broadly (125 awards, $184.1 million). By dollar value, the same two DLA entities account for the majority, but three civilian agencies surface as material dollar customers: the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (4 awards, $169 million), the Department of State Bureau of Medical Services (4 awards, $121.4 million), and the Department of the Army's Joint PEO Chemical and Biological Defense (2 awards, $42.9 million). These five customers represent 89% of combined potential value across the portfolio.

Meridian holds three prime indefinite delivery vehicles. The largest is a single-award IDC with DLA Medical Supply Chain awarded December 5, 2025, with a ceiling of $226.44 million through December 4, 2028—a strategic contract reflecting the government's commitment to maintaining reliable nerve agent antidote supplies. The company also holds the MANDRAKE 3.0 IDIQ with the Department of State Bureau of Medical Services, a $100 million single-award vehicle established September 30, 2023, through September 29, 2025 (now extended), from which three delivery orders totaling $21.4 million have been issued for autoinjectors and training devices delivered globally to State Department personnel. A third vehicle is a $1.0 million Other Transaction IDV with the Department of Defense's Joint PEO Chemical and Biological Defense awarded June 3, 2024, authorizing product enhancements to nerve agent autoinjector reliability. Top parent vehicles by task-order count include a DLA IDC (SP020096D0001, 30 task orders) and another DLA IDC (SPM20005D0010, 30 task orders, $85.1 million combined potential value).

Recent signature awards include a $129.7 million definitive firm-fixed-price contract from HHS ASPR, Office of the Assistant Secretary for Preparedness and Response, awarded September 30, 2024, for DuoDote single-dose autoinjectors for the Strategic National Stockpile with performance through September 29, 2027; a $36.47 million delivery order from DLA Medical Supply Chain awarded April 7, 2026, for antidote treatment supplies through January 7, 2027; and a $17.96 million delivery order under MANDRAKE 3.0 from State Bureau of Medical Services awarded September 30, 2023, for autoinjectors and trainers with delivery through October 31, 2024. The company also supplied a $9.92 million emergency procurement contract from HHS ASPR in September 2023 (147,150 DuoDote units) and a $418,638 Total Small Business set-aside purchase order from the Office of the Assistant Secretary for Administration in January 2026—the only set-aside award in the recent footprint.

Activity has declined significantly: 13 awards in 2022 contracted to 2 awards by 2026. Three awards with combined potential value of $182.6 million face ultimate completion within the next twenty-four months, representing material recompete exposure for competitors. Award portfolio total is $1.72 billion in combined potential value, with $650.8 million (38%) currently obligated. Work is classified under NAICS 326 (Surgical and Medical Instrument Manufacturing—115 awards) and 325411 (Pharmaceutical Preparation Manufacturing—59 awards), with PSC distribution dominated by Drugs and Biologicals (231 awards) and Training Aids (119 awards). Meridian's parent company is Kindeva Drug Delivery LP, a for-profit limited liability partnership also engaged in federal contracting as a prime awardee and grant recipient.